Controlled Crystallization During Freeze-Drying - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Controlled Crystallization During Freeze-Drying
The authors discuss the preparation of lipophilic drug nanocrystals by controlled crystallization during freeze-drying.


Pharmaceutical Technology
Volume 35, Issue 8, pp. 58-62

Results and discussion


Figure 1: Dissolution profiles of tablets composed of a physical mixture (open symbols) and controlled crystallized dispersions (black symbols) of 35% w/w fenofibrate in mannitol. (n = 3–6; mean ± standard deviation). (FIGURE 1 IS COURTESY OF THE AUTHORS)
In-line Raman spectroscopy. The dissolution rate of the solid dispersion, which had been frozen on a precooled freeze-dryer shelf, was higher than the dissolution rate of the physical mixture (see Figure 1). Because the freeze-dried sample was fully crystalline (as determined by differential scanning calorimetry and X-ray powder diffraction, the difference in dissolution rate was likely caused by differences in drug crystal size. Therefore, the drug crystals in the controlled crystallized dispersion were smaller (probably in the nanosize range), than the drug crystals in the physical mixture (x50 = 13 µm, determined by laser diffraction).

Although both components in the solid dispersion were fully crystalline, it was not clear at what point during the process the drug and matrix material crystallized. Therefore, in-line Raman spectroscopy was used to measure crystallization during the freeze-drying procedure. The Raman spectra clearly show peaks corresponding to water (208–226 cm-1 ), TBA (725–763 cm-1 ), δ-mannitol (865–895 cm-1 ), and fenofibrate (1580–1610 cm-1 ).


Figure 2: Raman spectra during freeze-drying of the rapidly frozen sample during freezing (15 and 75 min), after the temperature was increased to –25 °C (500 min), and during drying (2963 min). The gray bars indicate the characteristic peaks of water (208–226 cm-1), tertiary butyl alcohol (725–763 cm-1), d-mannitol (865–895 cm-1), and fenofibrate (1580–1610 cm-1).
These peaks are clearly separated from each other (see Figure 2), so the crystallization of the individual components could be monitored throughout the process. To determine crystallization, the relative intensities of the individual peaks of fenofibrate, mannitol, and water were determined. An increase in the peak intensity indicates the formation of crystals of the corresponding component. Peak intensity cannot be used to determine crystallization of TBA because liquid TBA already shows a peak with a high intensity. Therefore, the width of this peak was used to determine the onset and end of crystallization (10). A narrowing of the peak indicates the start of the TBA crystallization.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
67%
Facility/environment problems
0%
Process development problems
0%
Production equipment downtime
0%
Raw material supply problems
33%
Regulatory restrictions
0%
Business decisions to limit production
0%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced
Source: Pharmaceutical Technology,
Click here